Gainers

• Indaptus Therapeutics (NASDAQ:INDP) shares moved upwards by 34.0% to $1.26 during Thursday's regular session. The company's market cap stands at $125.2 million.
• BioVie (NASDAQ:BIVI) stock rose 30.85% to $1.75. The company's market cap stands at $10.1 million.
• Actuate Therapeutics (NASDAQ:ACTU) stock moved upwards by 16.98% to $1.24. The company's market cap stands at $25.4 million. As per the press release, Q2 earnings came out 4 days ago.
• Scribe Therapeutics (NASDAQ:SCTX) shares moved upwards by 16.26% to $36.1. The company's market cap stands at $502.4 million.
• Maravai LifeSciences (NASDAQ:MRVI) stock moved upwards by 13.71% to $8.21. The company's market cap stands at $1.0 billion.
• Prelude Therapeutics (NASDAQ:PRLD) shares moved upwards by 13.37% to $6.55. The company's market cap stands at $461.2 million.

Losers

• Profusa (NASDAQ:PFSA) stock decreased by 46.7% to $7.24 during Thursday's regular session. The company's market cap stands at $7.1 million. As per the news, the Q2 earnings report came out today.
• Tenon Medical (NASDAQ:TNON) shares decreased by 39.71% to $6.88. The market value of their outstanding shares is at $7.6 million.
• Moderna (NASDAQ:MRNA) shares decreased by 25.72% to $129.53. The market value of their outstanding shares is at $69.1 billion.
• OSR Health (NASDAQ:OSRH) shares fell 24.11% to $0.28. The company's market cap stands at $13.1 million. The company's, Q2 earnings came out 4 days ago.
• Matinas BioPharma Hldgs (AMEX:MTNB) shares decreased by 22.2% to $0.19. The company's market cap stands at $3.5 million.
• AIxCrypto Hldgs (NASDAQ:AIXC) stock decreased by 22.02% to $1.21. The company's market cap stands at $31.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.